Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

N-acetyl-L-leucine improves symptoms and functioning in GM2 Gangliosidosis (Tay-Sachs & Sandhoff)

View ORCID ProfileKyriakos Martakis, Jens Claassen, Jordi Gascon-Bayarri, Nicolina Goldschagg, Andreas Hahn, Anhar Hassan, Anita Hennig, Simon A. Jones, Heather Lau, Susan Perlman, Reena Sharma, Susanne A. Schneider, Tatiana Bremova-Ertl
doi: https://doi.org/10.1101/2021.09.24.21264020
Kyriakos Martakis
1Department of Pediatric Neurology, University Children’s Hospital (UKGM) and Medical Faculty, Justus Liebig University of Giessen, Giessen, Germany
2Department of Pediatrics, Medical Faculty and University Hospital, University of Cologne, Cologne, Germa
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kyriakos Martakis
  • For correspondence: kyriakos.martakis{at}paediat.med.uni-giessen.de
Jens Claassen
3Department of Neurology, Essen University Hospital, University of Duisburg-Essen, Germany; Department of Neurocritical Care, Neurological and Neurosurgical First Stage Rehabilitation and Weaning, MediClin Klinik Reichshof, Germany
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jordi Gascon-Bayarri
4Department of Neurologic Diseases and Neurogenetics, Institut d’Investigació Biomèdica de Bellvitge, Barcelona, Spain
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolina Goldschagg
5Department of Neurology, Ludwig Maximilian University of Munich, Germany
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Hahn
1Department of Pediatric Neurology, University Children’s Hospital (UKGM) and Medical Faculty, Justus Liebig University of Giessen, Giessen, Germany
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anhar Hassan
6Department of Neurology, Mayo Clinic, Rochester, MN, United States
MBBCh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anita Hennig
4Department of Neurologic Diseases and Neurogenetics, Institut d’Investigació Biomèdica de Bellvitge, Barcelona, Spain
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon A. Jones
7Willink Unit, Manchester Centre for Genomic Medicine, Royal Manchester Children’s Hospital, University of Manchester, United Kingdom
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather Lau
8Division of Neurogenetics, New York University Langone, NY, United States
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Perlman
9Department of Neurology, University of California Los Angeles, CA, United States
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reena Sharma
10Department of Adult Metabolic Medicine, Salford Royal Foundation NHS Trust, United Kingdom
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanne A. Schneider
5Department of Neurology, Ludwig Maximilian University of Munich, Germany
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatiana Bremova-Ertl
11Department of Neurology, University Hospital Bern (Inselspital), Switzerland
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background and Objective GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are rare, inherited neurodegenerative disorders with no available symptomatic or disease modifying treatments. This clinical trial aimed to investigate the safety and efficacy of N-acetyl-L-leucine (NALL) on symptoms of pediatric (≥ 6 years) and adult patients with GM2 gangliosidosis.

Methods \We conducted an 8-center, multi-national, open-label, rater-blinded Phase IIb study (IB1001-201). Patients with a genetically confirmed diagnosis of GM2 gangliosidosis were assessed during a baseline period, a 6-week treatment period (orally administered NALL 4 g/day in patients ≥13 years, weight-tiered doses for patients 6-12 years), and a 6-week post-treatment washout period. The primary Clinical Impression of Change in Severity (CI-CS) endpoint (based on a 7-point Likert scale) was assessed by blinded, centralized raters who compared randomized video pairs of each patient performing a pre-defined primary anchor test (8-Meter Walk Test or 9-Hole Peg Test) during each study periods. Secondary outcomes included cerebellar rating scales (namely Scale for the Assessment and Rating of Ataxia), clinical global impression, and quality of life assessments.

Results 30 patients aged 6 to 55 years with a confirmed diagnosis of GM2 gangliosidosis (Tay-Sachs or Sandhoff’s disease) were enrolled. 29 patients were included in the primary modified intention-to-treat analysis. NALL met the CI-CS primary endpoint (mean difference 0.71, SD=2.09, 90% CI 0.00, 1.50, p=0.044), as well as secondary endpoints. No treatment-related serious adverse events occurred.

Conclusions This study showed NALL led to a statistically significant improvement in symptoms, functioning, and quality of life in patients with GM2 gangliosidosis. It is a safe, well-tolerated, easily administered oral therapy, therefore offering a favorable risk/benefit profile for this serious, debilitating disorder. NALL is a new therapeutic option for the treatment of this rare disease that has no other approved therapies worldwide.

Classification of Evidence This study provides Class IV evidence NALL is safe, well-tolerated, and improves neurological symptoms and quality of life in patients with GM2 gangliosidosis.

Trial Registration Information The trial is registered with ClinicalTrials.gov (NCT03759665; registered 30-Nov-2018), EudraCT (2018-004406-25), and DRKS (DRKS00017539). The first patient was enrolled 07-June-2019.

Competing Interest Statement

T. Bremova-Ertl, J. Claassen and N. Goldschagg received fees for the blinded rater services from IntraBio. All other authors declare no competing interests. All other authors report no disclosures relevant to the manuscript.

Clinical Trial

NCT03759665

Funding Statement

The study was funded by IntraBio Ltd.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Approval for the study (clinicaltrials.gov identifier NCT03759639, EudraCT number 2018004331-71, and DR KS-ID: DRKS00016567) was obtained by National Regulatory Authorities in each country (German Federal Institute for Drugs and Medical Devices, Spain Agency of Medicines and Medical Devices, UK Medicines and Healthcare products Regulatory Agency, and US Food and Drug Administration), and the applicable responsible central research ethics committees / institutional review boards for each center (Ethics Committee of Ludwig Maximilian University of Munich (19-119), Bellvitge Hospital University Clinical Research Ethics Committee (AC004/19), North West - Greater Manchester South (260774) Mayo Clinic Institutional Review Board (19-000373), Office of Science and Research Institutional Review Board, New York University School of Medicine (i17-01666), University of California Los Angeles Institutional Review Board (19-000348)). Written informed consent was obtained for all study participants by the patient or, if applicable, their parent or legal representative.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. The study Sponsor, IntraBio Ltd. is committed to providing qualified scientific researchers appropriate access to anonymized data and clinical study information from the company's clinical trials for the purpose of conducting legitimate scientific research. Requests for specific data will be considered along with the rationale, description of use need, and clinical value of the proposed analysis. IntraBio supports an approach to sharing data that responsibly reflects the interests of all parties involved in clinical trials, including protecting the rights and privacy of trial participants, the innovator's intellectual property rights, and other incentives for innovation, and as such, will evaluate requests for sharing company clinical trial data with qualified external scientific researchers. Requests to access the data from this clinical trial may be made at info{at}intrabio.com. Data will be made available for request after product approval in the United States and European Union, after product development is discontinued, or as otherwise required by law or regulation. There are circumstances that may prevent IntraBio from sharing the requested data as the product is investigational at this time.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted September 27, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
N-acetyl-L-leucine improves symptoms and functioning in GM2 Gangliosidosis (Tay-Sachs & Sandhoff)
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
N-acetyl-L-leucine improves symptoms and functioning in GM2 Gangliosidosis (Tay-Sachs & Sandhoff)
Kyriakos Martakis, Jens Claassen, Jordi Gascon-Bayarri, Nicolina Goldschagg, Andreas Hahn, Anhar Hassan, Anita Hennig, Simon A. Jones, Heather Lau, Susan Perlman, Reena Sharma, Susanne A. Schneider, Tatiana Bremova-Ertl
medRxiv 2021.09.24.21264020; doi: https://doi.org/10.1101/2021.09.24.21264020
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
N-acetyl-L-leucine improves symptoms and functioning in GM2 Gangliosidosis (Tay-Sachs & Sandhoff)
Kyriakos Martakis, Jens Claassen, Jordi Gascon-Bayarri, Nicolina Goldschagg, Andreas Hahn, Anhar Hassan, Anita Hennig, Simon A. Jones, Heather Lau, Susan Perlman, Reena Sharma, Susanne A. Schneider, Tatiana Bremova-Ertl
medRxiv 2021.09.24.21264020; doi: https://doi.org/10.1101/2021.09.24.21264020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)